Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the annual meeting of stockholders held on September 8, 2017. The filing covers the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the annual meeting, 3,249,821 shares were present or represented by proxy out of 4,301,463 shares entitled to vote. The following matters were approved:
- Proposal 1 (Election of Class III Director): Mr. Jerry McLaughlin was elected. Votes cast: 829,230 FOR, 94,109 WITHHELD.
- Proposal 2 (Advisory Vote on Executive Compensation): Approved by stockholders. Votes cast: 737,543 FOR, 164,001 AGAINST, 21,795 ABSTAIN.
- Proposal 3 (Ratification of Auditor): Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2018. Votes cast: 2,707,633 FOR, 40,516 AGAINST, 501,672 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting (approximately 75.5%).
- Confirm the tenure and background of the newly elected Class III director, Jerry McLaughlin.
- Review the definitive proxy statement filed on July 27, 2017, for details on the executive compensation package approved in Proposal 2.
- Check subsequent filings for the financial performance of the fiscal year ending March 31, 2018, for which Marcum LLP was ratified as auditor.